Skip to main content

Table 2 Raw incidence of gout at timepoints 3, 5, 10, 12 and 15 years of follow-up in the cohort in combined cohort, males and females

From: Longitudinal development of incident gout from low-normal baseline serum urate concentrations: individual participant data analysis

  Serum urate (mg/dL) N 3 Years 5 Years 10 Years 12 Years 15 Years
All <  4.00 2490 0.08% 0.20% 0.46% 0.52% 0.59%
4.00–4.49 1896 0.27% 0.32% 0.71% 0.94% 1.28%
4.50–4.99 2383 0.13% 0.30% 0.65% 0.75% 0.86%
5.00–5.49 2535 0.16% 0.24% 0.83% 0.94% 0.94%
5.50–5.99 2363 0.13% 0.34% 0.93% 1.27% 1.52%
6.00–6.49 2192 0.28% 0.51% 1.33% 1.73% 2.91%
6.50–6.99 1810 0.22% 0.45% 1.96% 2.81% 3.20%
≥7.00 3220 1.44% 3.41% 7.95% 10.44% 12.22%
Males <  4.00 202 0.53% 1.61% 2.25% 2.25% 2.25%
4.00–4.49 291 0.00% 0.35% 1.09% 1.74% 2.41%
4.50–4.99 594 0.51% 0.51% 1.06% 1.06% 1.41%
5.00–5.49 968 1.41% 1.41% 0.57% 0.80% 0.80%
5.50–5.99 1226 0.17% 0.42% 0.93% 1.31% 1.71%
6.00–6.49 1365 0.37% 0.74% 1.44% 1.80% 3.35%
6.50–6.99 1260 0.32% 0.56% 1.97% 3.03% 3.50%
≥7.00 2374 1.66% 3.80% 7.87% 9.84% 11.38%
Females <  4.00 2288 0.04% 0.09% 0.32% 0.38% 0.45%
4.00–4.49 1605 0.25% 0.32% 0.64% 0.78% 1.06%
4.50–4.99 1789 2.31% 0.23% 0.52% 0.66% 0.66%
5.00–5.49 1567 0.26% 0.39% 0.99% 0.99% 0.99%
5.50–5.99 1137 0.09% 0.27% 0.92% 1.21% 1.21%
6.00–6.49 827 0.12% 0.12% 1.15% 1.72% 1.72%
6.50–6.99 550 2.44% 0.19% 1.97% 1.97% 1.97%
≥7.00 846 0.84% 2.30% 8.19% 13.06% 16.45%